Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
Events Partner Content 5th Annual Targeted Protein Degradation Summit Deliver Next Generation Degraders to Patients Faster
Events Partner Content 9th Annual Neurodegenerative Drug Development Summit Translate Neurodegenerative R&D Into the Clinic
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face